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ABSTRACT
Introduction: Idiopathic pulmonary fibrosis (IPF) is a
progressive, life-threatening illness of unknown
aetiology, with no proven pharmacological treatments.
There is a limited evidence base indicating that the
disease negatively affects quality of life, leading to
increased dependence, restrictions on daily activities
and fatigue. However, there is a paucity of in-depth
information on disease impact across its trajectory,
particularly in relation to unmet needs, outcomes of
importance to patients and the experiences of carers.
Furthermore, little is known about the support and
information needs of individuals and their carers, or at
what point individual need should trigger a referral to
palliative care services.
Methods and analysis: A mixed-methods study is
proposed recruiting individuals with IPF at different
stages of the disease and their carers from three
respiratory centres in England and Wales. In-depth
interviews will be undertaken with participants,
adopting an Interpretative Phenomenological Analysis
approach. The study will also use validated
questionnaires to explore quality of life (EQ-5D),
depression (Hospital Anxiety and Depression Scale),
breathlessness (Borg dyspnoea scale) and cough
(Leicester Cough Questionnaire, Cough Symptom
Score).
Ethics and dissemination: Ethical approvals were
gained in April 2012. Palliative care research is a
developing field, but there has been limited focus on
IPF. We anticipate that the results of the study will
enable healthcare professionals to provide appropriate
palliative care across the trajectory for individuals with
the disease, and their carers, and we therefore aim to
disseminate via relevant respiratory and palliative care
journals and conferences. We will also support the lay
representative involved in the project to disseminate
the findings to patient groups.
INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) is a pro-
gressive, life-limiting condition characterised
by chronic inﬂammation and scarring,1
causing breathlessness and a dry cough in
the individual.2 The aetiology of IPF is
unknown and the disease is progressive.3 The
illness trajectory of IPF is variable and a study
from the UK found that individuals lived
with the disease for a median of 3 years
before death,4 which is usually due to
respiratory failure.2 Identifying the preva-
lence of IPF is challenging as no mandatory
ARTICLE SUMMARY
Article focus
▪ Idiopathic pulmonary fibrosis is a progressive,
life-threatening illness with high symptom
burden. However, there has been very limited
research into patient perception of need, carer
burden or patient/carer defined outcomes of
importance in this population.
▪ A cross-sectional mixed-methods study is pro-
posed to explore the experiences and needs of
individuals and their carers across the illness tra-
jectory of IPF.
Key messages
▪ The findings from this study should influence
the care provided across the illness trajectory,
particularly in terms of the information needs of
individuals and carers at different stages of the
disease, and identification of triggers for pallia-
tive care service involvement.
▪ The study will also determine outcomes of
importance to patients which might influence
clinical service evaluation and the design of
future interventional studies in IPF.
Strengths and limitations of this study
▪ While this study is cross-sectional, rather than
longitudinal, a large sample of patients at differ-
ent stages of the disease, as well as their rela-
tives, will be included.
▪ This multicentre study in England and Wales will
also adopt a mixed-methods approach, including
qualitative interviews and the use of validated
questionnaires.
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monitoring register exists, but the overall incidence in
the UK is 7.44/100 000, with more men and older
people affected.5 While anti-inﬂammatory, immunosup-
pressant and antiﬁbrotic medications are prescribed for
IPF;1 no pharmacological treatments are proven to treat
IPF,6 with the only signiﬁcant treatment intervention
being lung transplantation.
Lee et al7 describe a holistic approach to care for indivi-
duals with IPF, including disease-management (including
medications), promoting education and self-management
and symptom management. They further assert that pallia-
tive care should be fundamental and central to the man-
agement of IPF,7 which has been similarly encouraged in
recent clinical guidance from the National Institute for
Health and Care Excellence in the UK.8 Palliative care is
deﬁned by the WHO 9 as:
an approach that improves the quality of life of patients
and their families facing the problem associated with life-
threatening illness, through the prevention and relief of
suffering by means of early identiﬁcation and impeccable
assessment and treatment of pain and other problems,
physical, psychosocial and spiritual
However, there is a paucity of research considering at
what stage palliative care should be offered to indivi-
duals with IPF, and what care and support patients feel
would beneﬁt them.
This protocol therefore describes a proposed cross-
sectional mixed-methods study (CaNoPy: Care Needs of
individuals with idiopathic Pulmonary ﬁbrosis and their
carers) designed to investigate the needs and experi-
ences of individuals with IPF, and their carers, across the
illness trajectory.
Literature review
A literature search was undertaken using MEDLINE,
CINAHL and PubMed, with additional hand-searching
of reference lists, to identify individuals’ and carers’
experiences of IPF and the impact of the disease on
their quality of life (QOL). The search identiﬁed several
studies considering QOL for individuals with IPF, but
fewer studies used a qualitative approach to explore
their experiences of the disease. A dearth of studies
focusing on the experiences of carers/family members
is also noted.
QOL and IPF
The WHO10 deﬁnes QOL as an individual’s “perception
of their position in life in the context of the culture and
value systems in which they live and in relation to their
goals, expectations, standards and concerns” (p.7).
Furthermore, Swigris et al11 assert that health-related
QOL is an individual’s “perception of the impact of
health (in all its many facets) on his or her quality of
life” (p.588). A systematic review by Swigris et al11
revealed that a small number of studies consider the
QOL of individuals with IPF. After a methodical
literature search, Swigris et al11 identiﬁed only seven
studies that assessed QOL in a total of 512 adults with
IPF. The included studies, which used the Medical
Outcomes Study Short-Form 36-item tool (SF-36), the
WHO-QOL 100-item tool or the St George’s Respiratory
Questionnaire, were conducted in Japan, the
Netherlands, Brazil and the USA.11 Health-related QOL
was found to be signiﬁcantly lower than the general
population in almost all domains, but particularly phys-
ical aspects such as respiratory symptoms, energy levels
and degrees of independence.11 Speciﬁcally, dyspnoea
was associated with worse QOL.11
Recent studies considering QOL have been identiﬁed
since Swigris et al’s11 systematic review. An American
cross-sectional study of 41 adults with IPF assessed
fatigue, sleep quality and QOL with the following vali-
dated tools: Pittsburgh sleep quality index, Epworth
sleepiness scale and SF-36.12 Participants in Krishnan
et al’s12 study reported signiﬁcantly poorer sleep than
the general population, and like Swigris et al11 identiﬁed
that QOL was signiﬁcantly reduced in most domains, in
particular physical aspects. Additionally, sleep quality was
associated with reduced QOL, which included physical
and emotional measures,12 and the authors thus recom-
mend interventions to improve sleep quality. Few studies
have adopted longitudinal approaches when considering
QOL in people with IPF. However, Tomioka et al13
adopted a cross-sectional and longitudinal approach,
measuring QOL using SF-36 at baseline (n=46) and
again at least 12 months later (n=32) for participants
who had not died, but developed other major diseases
or were lost to follow-up. At baseline, participants
reported signiﬁcantly reduced QOL compared with the
general population, while QOL had worsened signiﬁ-
cantly longitudinally in terms of physical function and
bodily pain.13
The small number of studies assessing the QOL of
people with IPF thus highlights signiﬁcantly reduced
outcomes, particularly in terms of physical health and
sleep quality. However, no studies were identiﬁed that
quantitatively measured relatives’ or carers’ QOL when
caring for an individual with this progressive terminal
disease. Nor have any studies explored in detail the
experiences underlying QOL deterioration or patient/
carer perceptions of interventions which might alter out-
comes of importance. Given the variable trajectory of
the disease, of particular interest is the identiﬁcation of
triggers for supportive and palliative interventions.
Qualitative experiences of IPF
Three studies were identiﬁed that explored the experi-
ences of individuals with IPF using qualitative methods,
although none of the studies discussed their methodo-
logical or philosophical approaches. Additionally, the
papers did not discuss the participants’ disease stages.
Swigris et al2 undertook focus groups or individual
interviews with 20 adults living with IPF in the USA. The
purpose of the study was to develop an IPF-sensitive
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health-related QOL measure by comparing the ﬁndings
of the study with commonly-used global or respiratory
tools. Dyspnoea and coughing were found to be distres-
sing and impaired QOL and medications for IPF caused
signiﬁcant side effects; sleep quality was affected; low
energy or exhaustion affected daily activities; forward
planning was necessary and employment was either
impossible or for some necessary to pay for medical
care.2 Furthermore, participants were concerned about
being a physical or ﬁnancial burden; appreciation was
expressed towards relatives; IPF led to decreased libido
or inability to undertake sexual activity; social activities
were limited and participants were fearful about their
health and recognised their mortality.2 The authors con-
cluded that an IPF-speciﬁc QOL instrument is required
as their participants’ perspectives of the disease were not
sufﬁciently reﬂected in generic tools.
Schoenheit et al14 undertook single in-depth interviews
with 45 adults with IPF from the following ﬁve European
countries: Spain, Italy, UK, France and Germany.
Additionally, 18 relatives were present during the inter-
views, although the article provides little insight into
their experiences. The authors used psychological tech-
niques of asking participants to select images that
express their feelings and asking them to recall what was
said in a particular situation. The study also collated
details of symptoms and revealed that dyspnoea was
experienced by 68% of participants, 59% reported a
cough and 28% reported fatigue.14 The majority of par-
ticipants had experienced delayed diagnoses and criti-
cised the care they received, while a minority of
participants who were diagnosed promptly reported
their care more positively.14 Both groups, however,
reported rushed and insensitive diagnosis and a lack of
available information to them about the disease. IPF was
found to have a substantial impact on daily life in terms
of reduced independence, difﬁculty in continuing rela-
tionships and struggling ﬁnancially through being
unable to work.14
Recently, Bajwah et al15 interviewed eight patients with
IPF, four carers (related to different patients) and six
healthcare professionals in the UK. They highlighted
that patients and carers had limited understanding of
the disease, which made it difﬁcult to plan ahead, and
that patients had not discussed end-of-life preferences.15
While patients and carers reported feeling satisﬁed with
the care provided by the respiratory team, they also
reported a lack of coordination between different
healthcare professionals and teams.15
IPF thus has a broad negative impact on everyday life
for the individual, particularly in terms of increased
dependence on relatives, reduction in socialising, ﬁnan-
cial concerns, recognition of mortality and a dearth of
information. Bajwah et al15 included a small sample of
carers but did not explicate their needs while caring for
an individual with IPF, while Schoenheit et al’s14 study
included relatives but the authors made little reference
to them in their paper. Therefore, additional studies are
required to understand carer experiences of IPF and
what support they require to care for a relative with the
condition. Exploring the experiences of carers and their
needs is crucial in a condition that is terminal and will
thus require a high level of support from those closest to
the individual with IPF.
This protocol thus presents a study designed to
explore the perspectives of the individual with IPF and
their carer at different stages of the disease.
METHODS
Aim and objectives
Aim: The aim of this study is to explore the needs of
individuals with IPF and their families across the illness
trajectory.
Objectives
1. Identify changes in individuals’ and carers’ perceived
palliative care needs over the progression of IPF in
order to improve future service interventions.
2. Identify time points or triggers at which palliative
care services might effectively be introduced.
3. Deﬁne the speciﬁc information needs of individuals
and their carers.
4. Evaluate speciﬁcally the experiences and roles of the
carer.
Methodology and methods
The uncertain nature of disease progression makes a
longitudinal study difﬁcult to achieve in a set time
frame, and therefore a cross-sectional design with indivi-
duals at different stages of the IPF trajectory was chosen.
To meet the aim and objectives of the study, a mixed-
methods approach will be undertaken, encompassing
the use of validated assessment tools (QOL, anxiety and
depression and IPF symptoms) and in-depth interviews
utilising Interpretative Phenomenological Analysis (IPA)
methodology. Participants will be recruited and data col-
lected from three National Health Service (NHS)
respiratory centres, including two Health Boards within
Wales and one NHS Trust in England.
Recruitment and sampling
Individuals with IPF and their carers (a person of their
choice who contributes most to their care, or at an
earlier disease stage provides emotional support) will be
recruited from the three respiratory centres, where a
member of the clinical team will provide them with
information about the study. Eligibility for the study will
be decided by the clinical team according to a study pro
forma, which classiﬁes individuals at different stages on
the IPF trajectory and documents respiratory
comorbidities.
The inclusion criteria for individuals will be a diagno-
sis of IPF and receiving medical care for IPF at one of
the three centres, as well as the ability to give informed
consent and to communicate sufﬁciently to take part in
an interview. The inclusion criteria for carers include
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caring for an individual with IPF in the study, as well as
the ability to give informed consent and communicate
adequately to be interviewed. The exclusion criteria for
individuals with IPF and carers will be any factor that
prevents communication or comprehension. A disease
typology was generated by palliative and respiratory
consultants who are part of the research team to classify
four different stages of the disease. To provide an
insight into the individuals’, and thus the carers’, needs
across the disease trajectory, four groups of participants
(see table 1) will be recruited, including people with
1. Limited disease: forced vital capacity (FVC) greater
than 50% predicted and gas transfer (TLCO) greater
than 40% predicted;
2. Extensive disease: FVC less than 50% or TLCO less
than 40% predicted;
3. Progressive disease: a fall in either FVC greater than
10% or TLCO greater than 15% during the previous
12 months;
4. Stable disease: a fall of less than 10% in FVC or less
than 15% in TLCO in the previous 12 months.
Participants will be purposively sampled16 to represent
the four categories above, based on their FVC scores
contained in their clinical notes, for example, limited
progressive, limited stable, extensive progressive, exten-
sive stable. Congruent with the recommendations for
IPA, the sample size for each group will be 6–10 indivi-
duals with IPF and 6–10 carers per homogeneous
group,17 to represent a perspective rather than a popula-
tion. While the total sample size (n=48–80) is therefore
large for the methodology, it is necessary to gain insight
into the perspectives of the four groups of participants.
Potential participants will be provided with a partici-
pant information sheet, reply letter and stamped
addressed envelope by a member of the clinical team in
the respiratory clinic, and requested to return the reply
slip to the research team if they are happy to be con-
tacted to take part in the study. Willing participants will
then be telephoned by a researcher and an interview
will be arranged at a time and place convenient for
them.
Data collection
Three data collection methods will be used in this study:
recording of demographic and comorbidities data, ques-
tionnaires and in-depth interviews.
Comorbidities and demographic data: Demographic vari-
ables (age, marital status, location) and comorbidities
(in particular chronic obstructive pulmonary disease,
pulmonary hypertension and lung cancer) of individuals
with IPF will be recorded by clinicians at the clinic on a
case report form.
Questionnaires: Prior to the in-depth interview, indivi-
duals with IPF will be requested to complete a booklet
of questionnaires covering QOL, anxiety and depression
and symptoms of IPF. These questionnaires will enable
the research team to observe whether QOL, anxiety and
depression change over time and how these correlate
with dyspnoea and coughing.
1. QOL: a validated, global health-related QOL tool will
be used to evaluate QOL in the form of the EQ-5D,
which encompasses ﬁve questions on mobility, self-
care, usual activities, pain/discomfort and anxiety/
depression.18 Swigris et al19 designed and tested a
QOL assessment tool speciﬁcally for IPF (ATAQ-IPF),
but no other studies were identiﬁed that use this
tool, and therefore we opted for a more generic but
well-validated tool.
2. Anxiety and depression: the validated Hospital
Anxiety and Depression Scale includes 14 questions
and has been used widely across patient populations
and found to be of high speciﬁcity and sensitivity.20
3. Breathlessness: a systematic review21 found that dys-
pnoea assessment scales have not been validated for
use in palliative care, but it also identiﬁed that the
Borg dyspnoea scale, measuring severity of breathless-
ness on a numerical scale, appeared the most appro-
priate for use with this population.
4. Cough: the Leicester Cough Questionnaire is a
19-item self-completion tool measuring the physical,
psychological and social QOL in relation to living
with a chronic cough, which demonstrated high spe-
ciﬁcity and sensitivity.22 The Cough Symptom Score23
measures the severity of the cough on a visual ana-
logue scale.
The researcher will assist participants to complete the
questionnaires as required, which should take around
20 min, and this will occur before the interview to min-
imise the inﬂuence of topics discussed on questionnaire
completion.
In-depth interviews: IPA is a qualitative psychological
approach used to explore how people make sense of
major events in their lives.17 Three philosophical
approaches inﬂuence IPA17: exploring the lived experi-
ence (phenomenology); interpretation of the phenom-
enon (hermeneutics); exploring the particular rather
than attempting to generalise a group (idiography).
This methodology has previously been used successfully
to explore palliative care issues, with both patients24 and
healthcare professionals.25
Table 1 Participant group characteristics
Participant group and
characteristics
Limited
disease
Extensive
disease
Progressive disease 6–10
individuals with
IPF
6–10
individuals with
IPF
6–10 carers 6–10 carers
Stable disease 6–10
individuals with
IPF
6–10
individuals with
IPF
6–10 carers 6–10 carers
n=48–80
IPF, idiopathic pulmonary fibrosis.
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To enable access to detailed personal accounts of how
participants experience IPF,17 the research team will
utilise semistructured interviews with people with the
disease and their carers. The interviews will be con-
ducted at a place and time convenient for the partici-
pants, in their homes or a quiet clinic location or over
the telephone, if preferred. One researcher will conduct
the interviews across all sites. It is anticipated that the
interviews will last between 30 and 60 min, with the
interviewer terminating the discussion if they become
concerned that the participant is unwell or fatigued. We
aim to interview individuals with IPF and carers separ-
ately, as is common in qualitative studies with both
parties26 27 and recommended by Smith et al.17 If so,
relatives will be interviewed ﬁrst to allow individuals with
IPF to have a break between completing the question-
naire and being interviewed. However, participants will
be interviewed together if they prefer, which Cavers
et al28 allowed in their qualitative study due to their par-
ticipants with glioma struggling at times with communi-
cation. With the participants’ consent, interviews will be
audio-recorded and transcribed verbatim.
An interview schedule will be used (see box 1) which
will also enable participants to inﬂuence the agenda and
discuss topics pertinent to them.17 The interview process
is dynamic and iterative, and so the schedule will be
reviewed after the ﬁrst few interviews to assess whether
alterations are necessary based on interviewee priorities.
Data analysis
While the quantitative and qualitative data will be ana-
lysed separately using appropriate methods, a comple-
mentary analysis of both data sets will seek to deﬁne key
points or triggers for palliative care involvement. This
will enable the identiﬁcation of key components of parti-
cipants’ experiences of the IPF trajectory and clarify
what possible interventions could be of beneﬁt to
patients and carers.
Quantitative: The quantitative data will be analysed
using SPSS by a member of the research team who is a
statistician.
1. Descriptive statistics will be used to present the ques-
tionnaire data in graphic format and questionnaire-
speciﬁc methodologies will be employed.
2. Categorical data will be presented as proportions
with a 95% CI and continuous data as means with a
95% CI. The limited size of the data set means that
the analysis will be exploratory.
Qualitative: IPA data analysis involves considering each
case (participant) in turn and systematically interpreting
how participants have interpreted their experience,
before a narrative account of each case is developed.17
A six-step approach to data analysis is recommended by
Smith et al.17
1. Reading and rereading: listening to the interview and
reading the transcript to familiarise oneself with the
data and ensure that the participant is the focus of
the analysis.
2. Initial noting: reading the transcript and noting any-
thing important, including what is said (descriptive),
the context of this (linguistic) and identifying pat-
terns in the data and what these mean (conceptual).
3. Developing emerging themes: turning the notes into
themes by summarising what is important in the
transcript.
4. Connecting themes: this involves mapping how the
emergent themes ﬁt together.
5. Moving to the next case: repeating the process with
each case, ensuring that each case is treated individu-
ally by trying to bracket out the ﬁndings from previ-
ous cases.
6. Patterns across cases: examining the cases for connec-
tions, considering how themes from one case feature
in another and which themes are the strongest—
redeﬁning themes is common at this stage. The
result should be superordinate themes and themes
within.
The four different groups of participants will be ana-
lysed separately, with comparisons made between the
groups. The data will be primarily analysed by the
researcher responsible for data collection. Tong et al29
recommend research triangulation to promote a deeper
understanding of the phenomenon, and therefore 10%
of the data will be double coded for agreement by a
second member of the research team. Additionally, the
research team will confer on the analysis to ensure that
there is agreement across the themes.
ETHICS AND DISSEMINATION
Ethical considerations
The Research Governance Frameworks for England and
Wales30 31 and guidelines from the National Patient
Safety Agency32 were followed when designing the study.
Participants will have a minimum of 24 h to decide
whether to take part in the study, and the research team
will ensure that the participants are fully aware of the
details of the research prior to collecting written
informed consent. Informed consent, which is central to
ethical research,30 will be taken by the researcher con-
ducting the interview who is experienced at doing so, or
by a member of the clinical team who has undertaken
appropriate Good Clinical Practice (research) training.
The research team will ensure that all participants have
the capacity to consent in line with the Mental Capacity
Act.33 All data will be kept strictly conﬁdential according
to the principles of the Data Protection Act34 and stored
safely in the research unit.
There is growing impetus to include patients and the
public in health and social care research as members of
the research team, rather than solely as participants,
which Tischler et al35 argue encourages the research to
be relevant to patients. Therefore, in line with guidance
from Involving People36 and Involve,37 the study docu-
mentation was reviewed by a lay representative volunteer
at the research centre hosting the study. The research
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centre has a substantial model of consumer involvement
and the nominated study volunteer will be involved at all
stages of the study and will attend regular meetings as a
member of the research team.
Validity and reliability/rigour
Greene et al38 argue that mixed-methods studies enable
triangulation of results, thus increasing conﬁdence in
the ﬁndings of the research. Thus, utilising in-depth
interviews and multiple questionnaires to explore partici-
pants’ QOL and experience across the disease trajectory
should promote complementarity38 and deepen inter-
pretations from the study. Yardley39 asserts the character-
istics of ‘good’ qualitative research.
1. Sensitivity to context: the thorough literature review
for this study promotes sensitivity, which is supported
by the clinical and research expertise of the research
team;
2. Commitment and rigour and transparency and
coherence: encouraged through the proposed sys-
tematic and sufﬁcient sampling, experienced qualita-
tive researchers collecting data and a
multidisciplinary team of researchers analysing the
data systematically;
3. Impact and importance: the objectives of the study
are to generate evidence that can be translated into
clinical practice, particularly in relation to the infor-
mation and palliative service needs of individuals
with IPF and their carers.
Furthermore, we aim to promote validity in the use of
validated assessment tools with high speciﬁcity and
sensitivity.
Limitations
One limitation of this study is the cross-sectional rather
than longitudinal design. However, as previously
Box 1 Interview schedules
Individuals with idiopathic pulmonary fibrosis (IPF)
Diagnosis
1. What symptoms were you experiencing when you were first diagnosed with IPF? What made you seek medical attention?
2. When and how did you get diagnosed with IPF?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about your illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so, what and how useful was it?
Living with IPF
6. How does your illness affect you? How has it impacted on your quality of life?
7. How have you been coping with or managing your illness?
8. Which services have you been receiving?
9. What do you think about the support that you have been receiving from health professionals?
10. Are there any gaps in the care that you have been receiving? What else could be done to help you?
The future
11. What is your understanding of how your illness will progress? Do you feel you have enough information about this? What else would
you like to know?
12. Do you anticipate the need for more help later on? What kind of help do you think you might need?
Is there anything else you have thought of that you would like to mention or discuss now?
Carers
Diagnosis
1. When and how did you first learn about (patient’s name) illness?
2. What symptoms was (name) experiencing when they were first diagnosed with IPF? What made them seek medical attention?
3. Had you heard about the condition before? If yes, what did you know about it?
4. What information were you given about the illness? How useful did you find this information?
5. Did you seek out other information on IPF? If so, what and how useful was it?
Living with IPF
6. How does (name) illness affect them?
7. How have they been coping with these changes/managing their illness?
8. How does (name) illness affect you? How has it impacted on your quality of life?
9. How have you been coping with these changes?
10. Have you been receiving any professional support or assistance?
11. What do you think about the support that you and (name) have been receiving from health professionals?
12. Are there any gaps in the care that (name) has been receiving? What else could be done to help you both?
The future
13. What is your understanding of how (name) illness will progress? Do you feel you have enough information about this? What else
would you like to know?
14. Do you anticipate the need for more help later on? If so, what kind of help do you think might need?
Is there anything else you have thought of that you would like to mention or discuss now?
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discussed, a longitudinal design is extremely challenging
and resource intensive due to the progressive and unpre-
dictable nature of IPF. We believe that the chosen cross-
sectional design will provide representative data in an
efﬁcient and inclusive manner. Another limitation is the
use of questionnaires that have not been speciﬁcally vali-
dated for use with this clinical population. Therefore, we
have pragmatically selected tools that have been used
successfully with similar groups, are not too onerous for
participants to complete and provide a broad perspec-
tive of participants’ QOL and provide insight into the
impact of IPF symptoms on everyday life.
Dissemination
Palliative care research is a developing discipline with
signiﬁcant methodological challenges. It frequently aims
to assess complex interventions in heterogeneous, vul-
nerable populations. Successful outcomes depend on
robust methodological approaches which are comple-
mentary and which engage multidisciplinary research-
ers.40 41 Identifying key points of intervention and
outcomes of importance to patients are essential to the
development of well-designed pragmatic trials and the
implementation of efﬁcient, patient-focused clinical
services.
There is increasing focus on ensuring that palliative
care services are available to and accessed by individuals
with non-malignant diseases—with emphasis on need,
not diagnosis.42 IPF is, as previously discussed, an under-
researched disease. We anticipate that the results of this
study will provide fundamental information considering
the quantitative and qualitative experiences and needs
of individuals and their carers, and will therefore be dis-
seminated via relevant clinical and research journals and
international conferences, encompassing both palliative
care and respiratory specialties. The Chief Investigator
and three of the Co-Investigators are Consultant
Clinicians in palliative medicine and respiratory special-
ties, which will enable the planning and provision of
appropriate palliative care services for individuals with
IPF and their carers across the illness trajectory.
Furthermore, the lay representative involved with the
project will be supported to disseminate the results to
relevant patient groups.
This paper has explored the incidence and symptoms
of IPF, with discussion of the limited previous research
undertaken in this area in terms of QOL or experience
of the disease. A paucity of research considering the
experience and needs of carers was also identiﬁed. This
protocol has presented a planned multicentre mixed-
methods study in England and Wales with people at dif-
ferent stages of IPF and their carers, utilising validated
questionnaires and in-depth interviews. The results of
the study may help healthcare professionals to plan and
implement appropriate palliative care services for
people with IPF and appropriate support for their
carers.
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